Oncology

Your Article Summary

See Latest Articles

Giant cell tumour of bone
Current Opinion in Oncology, 06/18/09

Thomas DM et al. - In a study to determine new treatment options for pts with unresectable giant cell tumour of bone (GCT), it appears that denosumab presents a new treatment option for pts with previously untreatable GCT. The eventual role of denosumab and other targeted agents in the treatment of GCT and related disorders is currently the subject of active study.

• Recent discoveries have identified a key role for the osteoclast differentiation factor, receptor activator of nuclear factor kappa B (NF-κB) ligand (RANKL), in the genesis of GCT.
• Development of the fully human monoclonal antibody to RANKL, denosumab, has led to a clinical trial in unresectable GCT.

• This study demonstrated an 86% response rate, with comparable evidence of clinical benefit, and was well tolerated.
• Other pathways that may present targets for therapy include the hypoxia-angiogenesis axis and the colony stimulating factor 1 receptor.

Today in Bone/Cartilage...keeping you current

Receive free subspecialty "5-minute updates" via email

Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient
International Journal of Clinical Oncology, 10/30/09

Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI
The Journal of Nuclear Medicine, 08/26/09

Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases
Journal of Clinical Oncology, 09/14/09

See All of Bone/Cartilage